requirements applicable to the facility. The Settlement Agreement provides that Laclede will sell the Facility to Alton Steel Company for \$1,000,000. These funds will be placed in a trust to be used by Alton Steel to perform clean-up activities at the site according to an agreed order of priorities and under the supervision of the U.S. Environmental Protection Agency and Illinois Environmental Protection Agency. Laclede will also pay the United States \$100,000 to be placed in a Superfund special account.

Under the Settlement Agreement, Laclede will transfer its RCRA part B permit ("RCRA Permit") to Alton Steel, and Alton Steel will perform closure and corrective action work and take other steps required in the Agreement to bring the Alton mill back into compliance with the RCRA Permit. Alton Steel will receive a covenant not to sue under CERCLA Sections 106 and 107 and RCRA Section 7003 for "existing contamination" at the Site. Alton Steel will also receive a covenant not to sue under RCRA Section 3008(h) so long as it remains in compliance with the compliance plan. Finally, Laclede will assign its rights under any applicable insurance policies to Alton Steel, and Alton Steel will seek to recover under such policies, with the proceeds to be used in remediating the Facility.

The Department of Justice will receive for a period of thirty (30) days from the date of this publication comments relating to the Settlement Agreement. Comments should be addressed to the Assistant Attorney General, Environment and Natural Resources Division, P.O. Box 7611, U.S. Department of Justice, Washington, DC 20044–7611, and should refer to *In re: Laclede Steel Company*, D.J. Ref. 90–7–1–07324/1. Commenters may request an opportunity for a public meeting in the affected area, in accordance with Section 7003(d) of RCRA, 42 U.S.C. 6973(d).

The Settlement Agreement may be examined at the Office of the United States Attorney, 111 South 10th Street, 20th Floor, St. Louis, Missouri, and at U.S. EPA Region 5, 77 West Jackson Boulevard, Chicago, IL 60604. A copy of the Settlement Agreement may also be obtained by mail from the Consent Decree Library, P.O. Box 7611, U.S. Department of Justice, Washington, DC 20044-7611 or by faxing or e-mailing a request to Tonia Fleetwood (tonia.fleetwood@usdoj.gov), fax no. (202) 514-0097, phone confirmation number (202) 514-1547. In requesting a copy from the Consent Decree Library, please enclose a check in the amount of

\$15.00 (25 cents per page reproduction cost) payable to the U.S. Treasury.

William D. Brighton,

Assistant Chief, Environmental Enforcement Section, Environment and Natural Resources Division.

[FR Doc. 03–2833 Filed 2–5–03; 8:45 am] BILLING CODE 4410–15–M

DEPARTMENT OF JUSTICE

Notice of Lodging of Consent Decree Pursuant to the Comprehensive Environmental Response Compensation and Liability Act ("CERCLA")

Pursuant to section 122(d) of CERCLA, 42 U.S.C. 9622(d), and 28 CFR 50.7 notice is hereby given that on January 13, 2003, a proposed Consent Decree in *United States* v. *Regional Refuse District No. 1, et al.*, Civ. No. 3:03CV84 (PCD), was lodged with the United States District Court for the District of Connecticut.

In this action the United States sought recovery of costs incurred, and injunctive relief requiring performance of response actions at the Barkhamsted-New Hartford Landfill Superfund Site located adjacent to and southwest of Route 44, in the Towns of Barkhamsted and New Hartford, Connecticut. The Consent Decree requires that the settling parties pay \$483,304.55 in reimbursement of past response costs; implement EPA's September 28, 2001 Record of Decision ("ROD"); pay the governments' future oversight costs; and implement certain institutional controls, including recordation of land/water use restrictions.

The Department of Justice will receive, for a period of thirty (30) days from the date of this publication, comments relating to the Consent Decree. Comments should be addressed to the Assistant Attorney General, Environment and Natural Resources Division, P.O. Box 7611, U.S. Department of Justice, Washington, DC 20044–7611, and should refer to *United States v. Regional Refuse District No. 1*, et al., Civ. No. 3:03CV84 (PCD), D.J. Ref. No. 90–11–2–830/1.

The Consent Decree may be examined at the Office of the United States Attorney, 157 Church Street, 23rd Floor, New Haven, CT, and at U.S. EPA Region I, 1 Congress Street, Suite 1100, Boston, MA. A copy of the Consent Decree may also be obtained by mail from the Consent Decree Library, P.O. Box 7611, U.S. Department of Justice, Washington, DC 20044–7611 or by faxing a request to Tonia Fleetwood, fax no. (202) 514–0097, phone confirmation number (202)

514–1547. In requesting a copy, please enclose a check in the amount of \$58.50 (25 cents per page reproduction cost) payable to the U.S. Treasury. In requesting a copy exclusive of exhibits, defendants' signatures, and appendices, please enclose a check in the amount of \$11.25 (25 cents per page reproduction cost) payable to the U.S. Treasury.

Ronald Gluck,

Assistant Section Chief, Environmental Enforcement Section, Environment and Natural Resources Division.

[FR Doc. 03–2831 Filed 2–5–03; 8:45 am] ${\tt BILLING\ CODE\ 4410–15-M}$

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.33(a) of title 21 of the Code of Federal Regulations (CFR), this is notice that on October 23, 2002, AccuStandard, Inc., 125 Market Street, New Haven, Connecticut 06513, made application by letter to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below:

Drug	Schedule
Drug Cathinone (1235)	Schedule I I I I I I I I I I I I I I I I I I
4-Methoxyamphetamine (7411) Bufotenine (7433)1-[1-(2-	
Thienyl)cyclohexyl]piperidine (7470). Codeine-N-oxide (9053)	
Dihydromorphine (9145)	li

Drug	Schedu
Heroin (9200)	ı
Morphine-N-oxide (9307)	1
Normorphine (9313)	1
Etonitazene (9624)	1
Amphetamine (1100)	II
Methamphetamine (1105)	II
Phenmetrazine (1631)	II
Methylphenidate (1724)	II
Amobarbital (2125)	II
Pentobarbital (2270)	II
Secobarbital (2315)	II
Glutethimide (2550)	II
Phencyclidine (7471)	II
Alphaprodine (9010)	II
Anileridine (9020)	II
Cocaine (9041)	II
Codeine (9050)	II
Diprenorphine (9058)	II
Dihydrocodeine (9120)	II
Hydromorphone (9150)	II
Diphenoxylate (9170)	II
Benzoylecgonine (9180)	II
Ecgonine (9180)	II
Hydrocodone (9193)	II
Levorphanol (9220)	II
Methadone (9250)	II
Morphine (9300)	II
Thebaine (9333)	II
Opium, raw (9600)	II
Opium tincture (9630)	II
Opium powdered (9639)	II
Levo-alphacetylmethadol (9648)	II
Oxymorphone (9652)	II
Alfentanil (9737)	II
Sufentanil (9740)	II
Fentanyl (9801)	II

The firm plans to manufacture small quantities of the listed controlled substances to make reference standards.

Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration.

Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: DEA Federal Register, Representative (CCR), and must be filed no later then April 7, 2003.

Dated: January 27, 2003.

Laura M. Nagel,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 03-2919 Filed 2-5-03; 8:45 am]

BILLING CODE 4410-09-M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.33(a) of title 21 of the Code of Federal Regulations (CFR), this is notice that on July 3, 2002, American Radiolabeled Chemicals, Inc., 11624 Bowling Green Drive, St. Louis, Missouri 63146, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below:

le

Drug	Schedul
Gamma hydroxybutyric acid (2010).	1
Lysergic acid diethylamide (7315)	1
Dimethyltryptamine (7435)	1
Dihydromorphine (9145)	1
Phencyclidine (7471)	II
Cocaine (9041)	II
Codeine (9050)	II
Hydromorphone (9150)	II
Oxycodone (9143)	II
Thebaine (9333)	II
Benzoylecgonine (9180)	II
Meperidine (9230)	II
Metazocine (9240)	II
Morphine (9300)	II
Oxymorphone (9652)	II

The firm plans to bulk manufacture small quantities of the listed controlled substances as radiolabeled compounds.

Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration.

Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: DEA Federal Register Representative (CCR), and must be filed no later than April 7, 2003.

Dated: January 27, 2003.

Laura M. Nagel,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 03–2916 Filed 2–5–03; 8:45 am]

BILLING CODE 4410-09-M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.33(a) of title 21 of the Code of Federal Regulations (CFR), this is notice that on July 31, 2002, Cerrilliant Corporation, 811 Paloma Drive, Suite A, Round Rock, Texas 78664, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below:

controlled substances fisted below.	
Drug	Schedule
Cathinone (1235)	1
Methcathinone (1237)	i
N-Ethylamphetamine (1475)	i
N,N–Dimethylamphetamine	i
(1480).	•
Aminorex (1585)	1
4-Methylaminorex (cis isomer)	i
(1590).	'
Gamma hydroxybutyric acid	1
	'
(2010).	
Methaqualone (2565)	
Alpha-Ethyltryptamine (7249)	!
Lysergic acid diethylamide (7315)	
Tetrahydrocannabinols (7370)	!
Mescaline (7381)	!
3,4,5-Trimethoxyamphetamine	I
(7390).	_
4-Bromo-2,5-	I
dimethoxyamphetamine (7391).	
4-Bromo-2,5-	ı
dimethoxyphenethylamine	
(7392).	
4-Methyl-2,5-	1
dimethoxyamphetamine (7395).	
2,5-Dimethoxyamphetamine	1
(7396).	
2,5-Dimethoxy-4-	1
ethylamphetamine (7399).	
3,4-Methylenedioxyamphetamine	1
(7400).	
5-Methoxy-3,4-	1
methylenedioxyamphetamine	
(7401).	
N-Hydroxy-3,4-	1
methylenedioxyamphetamine	
(7402).	
3,4-Methylenedioxy-N-	1
ethylamphetamine (7404).	•
3,4-	1
Methylenedioxymethamphetam-	•
ine (7405).	
4-Methoxyamphetamine (7411)	1
Bufotenine (7433)	i
Diethyltryptamine (7434)	i
Dimethyltryptamine (7435)	i
Psilocybin (7437)	i
	i
Psilocyn (7438)	:
Acetyldihydrocodeine (9051)	1
Benzylmorphine (9052)	i
Codeine-N-oxide (9053)	·='
Dihydromorphine (9145)	ļ
Heroin (9200)	1
Hydromorphinol (9301)	
Methyldihydromorphine (9304)	
Morphine-N-oxide (9307)	l I